Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
April 16, 2026Hepatology CommunicationsOpen Access

Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis

View Full Paper
Ask AI
Bookmark
Share

Authors

UBU. BeuersARAlexandra RousseauSGStan F.J. van de Graaf

Discussion

Loading...

Member takes

Overview

Post hoc analysis finds varying fracture risks among PPAR agonists in PBC, indicating potential safety concerns.

Key Points

  • This analysis aims to evaluate the fracture risk associated with different PPAR agonists in patients with primary biliary cholangitis (PBC).
  • Post hoc analysis of randomized, placebo-controlled trials
  • Assessment of fracture incidence in PBC patients on selective and non-selective PPAR agonists
  • Comparison of serum vitamin D levels and deficiency rates across groups
  • Analysis of cumulative fractures over a 2-year treatment period
  • Seladelpar group reported 4.1 fractures per 100 person-years; no fractures in placebo group
  • Elafibranor group had up to 6.5 fractures per 100 person-years; none in placebo group
  • Bezafibrate showed similar fracture rates as placebo, with no significant difference reported.

Cite This Study

Beuers et al. (2026) studied this question.

synapsesocial.com/papers/69e07c1e2f7e8953b7cbd8e3https://doi.org/10.1097/hc9.0000000000000945
View Full Paper
Ask AI
Bookmark
Share